Table 1. Summary of key adverse events... | American Society of Hematology

Table 1.

Summary of key adverse events related to targeted agents studied in CLL

Darker red indicates a higher incidence of any grade AE. 17p, patients with deletion 17p; AE, adverse event; TN, treatment-naïve; RR, relapsed/refractory disease; +Ofa, combination therapy with ofatumumab; +R, combination therapy with rituximab; NR, not reported.

Median time on study treatment. Median follow-up was not reported.

View Large

This Feature Is Available To Subscribers Only